Nutriband Inc. is moving closer to developing the world's first opioid pain patch with abuse-deterrent properties, according to recent statements by CEO Gareth Sheridan. The company has established a strategic partnership with Kindeva Drug Delivery, a leading contract development and manufacturing organization, to advance its proprietary AVERSA Fentanyl technology.
The collaboration represents a critical milestone in Nutriband's efforts to address a significant challenge in pain management: preventing opioid medication misuse. By focusing on developing an abuse-deterrent transdermal patch, the company aims to provide a safer alternative to traditional opioid pain treatments.
Sheridan highlighted the partnership as a key component of the company's strategic roadmap, signaling potential advancements in pharmaceutical drug delivery that could have far-reaching implications for patient safety and healthcare. The development of AVERSA Fentanyl could represent a significant breakthrough in mitigating the risks associated with opioid medications.
The ongoing work with Kindeva Drug Delivery demonstrates Nutriband's commitment to scaling up manufacturing processes and bringing the AVERSA technology closer to commercial viability. This progress suggests the potential for a novel approach to pain management that prioritizes patient safety while maintaining effective treatment options.
